Yandong Shen, PhD

CLL research fellow
Royal North Shore Hospital, Australia

n/a

Poster(s):

• 1132 - Very low COVID mortality and hospitalization rates in CLL and MBL with repeated vaccination to maximum antibody response

• 1162 - Time-limited venetoclax-rituximab is effective for patients with Bruton tyrosine kinase exposed chronic lymphocytic leukaemia, but durable treatment-free remissions are uncommon